Welcome to the HTL blog!

Skin quality has become one of the main focuses of modern aesthetic medicine. While traditional treatments have often aimed to correct visible signs of ageing, today’s regenerative approaches seek to improve the skin itself by supporting hydration, structure and tissue regeneration.

Hyaluronic acid (HA) has become the dominant biomaterial in injectable soft tissue augmentation, with millions of treatments performed annually worldwide. As a naturally occurring glycosaminoglycan composed of repeating disaccharide units of D-glucuronic acid and N-acetyl-D-glucosamine, native HA possesses exceptional biocompatibility, hygroscopicity, and viscoelastic properties. However, in its unmodified state, HA is rapidly degraded in vivo by endogenous hyaluronidases and reactive oxygen species, with a tissue half-life measured in hours to days. [1,2]

To overcome this limitation and create materials suitable for lasting soft tissue correction, HA must be chemically cross-linked. This process transforms a fluid polysaccharide solution into a structured hydrogel with tuneable mechanical and biological properties. The chemistry of cross-linking is, in many respects, the defining step that determines how a dermal filler will perform in the hands of a clinician and in the tissues of a patient. [2,3]

On January 29, 2026, during IMCAS World Congress in Paris, HTL Biotechnology hosted its first scientific session dedicated to the future of regenerative and aesthetic medicine.

Bringing together experts from industry and clinical practice, the session explored how advanced biopolymers are helping shift aesthetic medicine toward a more regenerative approach, focused on skin quality, tissue repair, and long-term biological function.

Polynucleotides (PN) play an increasingly important role in regenerative medicine and are now assessed against criteria such as biological quality, safety, traceability, and responsible sourcing. In this context, the origin of polynucleotides has become a structuring factor, influencing both the final product profile and the confidence of stakeholders across the medical value chain. Among the various available sources, polynucleotides derived from wild salmon stand out for a set of specific characteristics. 

Microneedles today represent a highly promising advancement in transdermal medicine and tissue drug delivery. At the interface between biomaterials, biotechnology, and pharmacology, they enable targeted and minimally invasive delivery of active compounds directly into the dermis and epidermis.

Recent studies demonstrate their potential in regenerative aesthetics, wound healing, immunology and oncology, particularly in the treatment of melanoma.

Osteoarthritis is a degenerative joint disorder, often leading to chronic pain and reduced mobility as cartilage deteriorates over time.

Due to its viscoelastic properties, Hyaluronic acid (HA), a naturally occurring molecule in the body and a major component of the extracellular matrix, is an ideal candidate for addressing these degenerative processes of joint diseases. Recognized for its lubricating properties, HA is also shaping the management of osteoarthritis and rheumatologic diseases through its multi-faceted therapeutic potential.

Since 1992, HTL Biotechnology has pioneered hyaluronic acid (HA) production through bacterial fermentation, achieving unmatched purity and consistency for applications in ophthalmology, dermatology, and rheumatology.